©The Author(s) 2023.
World J Cardiol. Apr 26, 2023; 15(4): 165-173
Published online Apr 26, 2023. doi: 10.4330/wjc.v15.i4.165
Published online Apr 26, 2023. doi: 10.4330/wjc.v15.i4.165
Table 2 Comparison between survivors and no survivors, n %
| Variable | All patients | Survivors (No. 28) | No survivors (No. 33) | P value |
| Clinical data | ||||
| Age (yr), mean ± SD | 54.3 ± 10.3 | 50.1 ± 11.6 | 58.0 ± 7.3 | 0.003 |
| Gender, M/F | 45/16 (73.8/26.2) | 18/10 (40.0/62.5) | 6/27 (60.0/37.5) | 0.121 |
| BMI (kg/m2), mean ± SD | 32.9 ± 5.3 | 31.8 ± 4.0 | 33.8 ± 6.1 | 0.138 |
| Charlson index, median (IQR) | 2.0 (1.0-3.0) | 2.0 (1.0-3.0) | 2.0 (1.0-3.0) | 0.772 |
| Time from symptoms’ onset to ICU (d), median (IQR) | 13 (10-13) | 10 (8-13) | 13 (10-15) | 0.066 |
| SOFA, median (IQR) | 8.0 (7.0-10.0) | 7.5 (5.5-9.0) | 10.0 (8.0-10.0) | 0.01 |
| Mechanical ventilation length to ECMO support (d), median (IQR) | 6.0 (8.0-11.0) | 6.5 (4.5-9.5) | 10.0 (7.0-12.0) | 0.006 |
| ECMO duration (d), median (IQR) | 22 (13-42) | 35 (19-48) | 18 (10-30) | 0.015 |
| ICU death | 33 (54.1) | - | - | - |
| Biohumoral data | ||||
| Creatinine (mg/dL), median (IQR) | 1.00 (0.70-1.88) | 0.82 (0.60-1.35) | 1.60 (0.77-2.00) | 0.03 |
| D-dimer (ng/mL), median (IQR) | 3694 (2153-7326) | 3948 (1740-13095) | 3600 (2378-5007) | 0.418 |
| CRP (mg/dL), median (IQR) | 140 (86-143) | 120 (85-172) | 164 (97-215) | 0.553 |
| IL-6 (pg/mL), median (IQR) | 35.5 (7.9-71.0) | 46.5 (6.8-107.0) | 35.5 (20.5-59.0) | 0.851 |
| Troponin (pg/mL), median (IQR) | 20.5 (15.0-39.0) | 34.0 (15.0-115.0) | 22.0 (9.0-50.0) | 0.281 |
| NT-pro BNP (pg/mL), median (IQR) | 875 (355-1754) | 734 (254-1542) | 1272 (586-1870) | 0.064 |
| LDH IU/L, median (IQR) | 466 (378-540) | 423 (367-513) | 475 (426-543) | 0.089 |
| Echocardiographic data | ||||
| LVEF (%) | 63.9 ± 7.6 | 65.6 ± 8.1 | 62.5 ± 6.9 | 0.113 |
| RV/LV | 0.58 ± 0.17 | 0.58 ± 0.19 | 0.58 ± 0.16 | 0.945 |
| TAPSE (mm) | 18.0 (10.0-21.0) | 19.0 (10.0 ± 22.5) | 18.0 (10.0-21.0) | 0.375 |
| RVDD | 34 (55.7) | 13 | 21 | 0.275 |
| sPAP (mmHg) | 58.4 ± 9.4 | 60.2 ± 7.6 | 61.3 ± 10.7 | 0.638 |
| E/e1 | 11 ± 3 | 10.7 ± 2.9 | 11.6 ± 3.7 | 0.34 |
| TAPSE/sPAP (mm/mmHg) | 0.28 ± 0.13 | 0.29 ± 0.13 | 0.27 ± 0.13 | 0.692 |
| Ventilatory parameters | ||||
| PEEP (cm H2O) | 12.2 ± 2.3 | 12.3 ± 2.3 | 12.2 ± 2.4 | 0.91 |
| PO2/FiO2 | 62 (50-88) | 66 (54-88) | 60 (50-88) | 0.442 |
| Norepinephrine (μg/kg/min), mean ± SD | 0.34 ± 0.22 | 0.30 ± 0.20 | 0.35 ± 0.24 | 0.388 |
- Citation: Lazzeri C, Bonizzoli M, Batacchi S, Cianchi G, Franci A, Socci F, Chiostri M, Peris A. Right ventricle dysfunction does not predict mortality in patients with SARS-CoV-2-related acute respiratory distress syndrome on extracorporeal membrane oxygenation support. World J Cardiol 2023; 15(4): 165-173
- URL: https://www.wjgnet.com/1949-8462/full/v15/i4/165.htm
- DOI: https://dx.doi.org/10.4330/wjc.v15.i4.165